{"id":6719,"date":"2024-10-30T05:39:00","date_gmt":"2024-10-29T22:39:00","guid":{"rendered":"https:\/\/www.globenewswire.com\/news-release\/2024\/10\/29\/2971317\/0\/en\/Actuate-to-Participate-in-Lantern-s-Pharma-Webinar-on-AI-Driven-Drug-Development.html2971317"},"modified":"2024-10-30T05:43:52","modified_gmt":"2024-10-29T22:43:52","slug":"actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development","status":"publish","type":"post","link":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/","title":{"rendered":"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development"},"content":{"rendered":"\n<ul>\n<li><em>Companies will discuss how Lantern\u2019s AI platform is being leveraged for the identification and&nbsp;development of enrichment biomarkers for Actuate\u2019s lead investigational drug product, elraglusib<\/em><\/li>\n<\/ul>\n<p align=\"left\">CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) &#8212; Actuate Therapeutics, Inc. (NASDAQ: ACTU) (\u201cActuate\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3\u03b2), announced that it will participate in \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lvht0OrBoPzhRtT20lHkjA9K8t1HTxa3ks42jXjfhUEEwp4VdgCu-Pbfpo3qNAGNMGJQaoJ5RRNvHbvsaK4PpytlfvTIm04Cp-EIuNMyFgR11DvY_UbKA1MzDi6aMetc\" rel=\"nofollow noopener\" target=\"_blank\" title><u>Webinar Wednesday<\/u><\/a>\u201d hosted by Lantern Pharma on October 30, 2024.<\/p>\n<p align=\"left\">Andrew Mazar, Ph.D., Chief Operating Officer of Actuate Therapeutics, and Joseph McDermott, Ph.D, Lantern\u2019s computational biologist will discuss <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ka-3IfSaGExpI3AkB7a55KtjJnAlbNc0g2ASjGRjD15951in9bZRqTLAt7NDfWNWFPqMM18qxOqz313nOqWouScA8ivKGCE30o4f7iG9hcxHKfzDkCmwPQ2rTb3nOGQb-6zx-5i6W6d9jw9vkX84CZsadfHjvaC3xeZL5giNfYcGjffpJum2oPcXTO0HwdR5slJVocDsNZxnX6NYMU_UkbgkdG89nt3IjuX4Vm0-eIU-WTYXGPeu5HoyV9ExaAGb1FR6O7BdvIBocyCnCMP2oahyhV-FTIEGlDxZU-f6gB1DEIxEtwOQIsM-zp5P1j9guUWh4TC3w-ILklwxwWUiYMhnyS_jeHBx7cTP3ZyJrls=\" rel=\"nofollow noopener\" target=\"_blank\" title><u>the multi-year research and development collaboration<\/u><\/a> that is accelerating the development of Actuate\u2019s lead drug candidate, elraglusib, and enabling the screening for additional biomarkers to assess and predict its therapeutic activity and clinical outcomes.<\/p>\n<p align=\"left\">To register for the webinar, please use the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LC4Jp47IRWvRt_V7rjU6fxOE4jMx7J0XCSabsfrUqvgnBPSPt33T40KvqxiSmqobW2MsZiKnzTI6XN-4f5On2SIYgWihDQi1BdMJmD_ldQxZCDZL0YptJVGkLPLPfLCXTCqx74FYK2A8KgzQS7hqto2RiMeYlEV00DiSG05XbZD6irpzvQ9ZTI4-Wjnf0Y2wzxAveLJ7imjWAYdS13koNo0uF3tvyuQqW1J4olemNgFW2T4qENWGqS0OjGDUuSudmQ-gT1ThgckmDOFXoT3sHa8GD3yJxCuEse3df44kf5AAXKt-OEMetY1Pc8d3A2T3G6IgYNLXY448JZ-EM5isMSIs5Y-OG7O0f0CKUusqJMd65C-zxOfcZjKcQzhHekjuTzs5P1nb6HrlenAWLnf6REmeDM1ITOtqJKYtB-Tc3oWSgA470gj_hAG4kBorUForGib0iBQnoBoUg4fSqoiFuqy_oXNQrIl13ZsVFiWWJl-y6wAswScUV-FwvCLJyNCpUxxPQmRWjFg_xi_o-q67QjebcL8EwcJcwRlnq13rdOJWjeDh1rBvXkLsmD59nNz6NZBVk1yUQ9JfXMmxmcRhx1jxwVtqHYE0BGd1q5rFdP0=\" rel=\"nofollow noopener\" target=\"_blank\" title><u>https:\/\/bit.ly\/3YsL2XN<\/u><\/a><\/p>\n<p align=\"left\">Elraglusib is a novel GSK-3\u03b2 inhibitor currently being evaluated in Phase 2 Trial in metastatic pancreatic cancer <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MbV5KScJ3cA7oqhQiJYlhzm-Q246-etZEvdlCxWMLcUD-CVci_i7MmLnbUpl-EoufGCqGUfdrJBCpLDwJXSixysN-nbbd9V8u2f93GgPVaZasPBLkkuH14RgjLd0WRlx\" rel=\"nofollow noopener\" target=\"_blank\" title>(<u>NCT03678883<\/u>)<\/a> and Phase 1\/2 Trial <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MbV5KScJ3cA7oqhQiJYlh6cytV897f8xLn-4iIUabsA7QN1ycAK9ScCibzWq8_h9wUWfbqFBctkNNwIWIZHOXORQ8cFOnXII7zlLjCbZS01ng4H1sLV49TE9IYbI-cmuStVIiiMDSNjOGYClhhHMXg==\" rel=\"nofollow noopener\" target=\"_blank\" title>(<u>NCT04239092<\/u>)<\/a> in Ewing Sarcoma (EWS) and EWS-related sarcomas.<\/p>\n<p align=\"left\"><strong>About Actuate Therapeutics, Inc.<\/strong><\/p>\n<p align=\"left\">Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate\u2019s lead investigational drug product, elraglusib (a novel GSK-3\u03b2 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including EMT, NF-kB-mediated resistance and several DDR pathways. Elraglusib also acts as a mediator of anti-tumor immunity through the inhibition of NF-kB in immune cells and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_kKeWpjNCmQ4RT5jUdDEvhqKkcf3j9Xe4YNdooIFHJV97RWzKXoSI0iMU5ZOatZgGKnaPeoANzLw670g2WxeVEEedVN442cy7allovxf50WIjYCctk0ISxgtK5RVjXPq\" rel=\"nofollow noopener\" target=\"_blank\" title><u>http:\/\/www.actuatetherapeutics.com<\/u><\/a>.<\/p>\n<p align=\"left\"><strong>Forward-Looking Statements<\/strong><\/p>\n<p align=\"left\">This press release contains and the webinar referenced above will contain forward-looking statements about us, including our clinical trials and development plans, and our industry. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201congoing,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release and the webinar are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve favorable results in clinical trials or preclinical studies or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; and our ability to fund development activities. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading \u201cRisk Factors\u201d in our Form 10-Q filed with the SEC on September 24, 2024 and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or the webinar or to reflect the occurrence of unanticipated events.<\/p>\n<p align=\"left\"><strong>Investor Contact <\/strong><\/p>\n<p align=\"left\">Mike Moyer<\/p>\n<p align=\"left\">Managing Director<\/p>\n<p align=\"left\">LifeSci Advisors, LLC<\/p>\n<p align=\"left\">mmoyer@lifesciadvisors.com<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmFhNzVkMmItNzY5MC00NzMwLWJiOTAtMzNmNWY1ODU1ZjcyLTUwMDEwMDA5Nw==\/tiny\/Actuate-Therapeutics.png\" referrerpolicy=\"no-referrer-when-downgrade\">  <\/p>\n","protected":false},"excerpt":{"rendered":"<p> Companies will discuss how Lantern\u2019s AI platform is being leveraged for the identification and\u00a0development of enrichment biomarkers for Actuate\u2019s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) &#8212; Actuate Therapeutics, Inc. (NASDAQ: ACTU) (\u201cActuate\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3\u03b2), announced that it will participate in \u201cWebinar Wednesday\u201d hosted by Lantern Pharma&#8230;<\/p>\n","protected":false},"author":1,"featured_media":6720,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[75,1406],"tags":[],"class_list":["post-6719","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-globenewswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development<\/title>\n<meta name=\"description\" content=\"Companies will discuss how Lantern\u2019s AI platform is being leveraged for the identification and\u00a0development of enrichment biomarkers for Actuate\u2019s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (\u201cActuate\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3\u03b2), announced that it will participate in \u201cWebinar Wednesday\u201d hosted by Lantern Pharma...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\" \/>\n<meta property=\"og:locale\" content=\"vi_VN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development\" \/>\n<meta property=\"og:description\" content=\"Companies will discuss how Lantern\u2019s AI platform is being leveraged for the identification and\u00a0development of enrichment biomarkers for Actuate\u2019s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (\u201cActuate\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3\u03b2), announced that it will participate in \u201cWebinar Wednesday\u201d hosted by Lantern Pharma...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Crypto Insider\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/yourcryptoinsider\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-29T22:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-29T22:43:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/NmFhNzVkMmItNzY5MC00NzMwLWJiOTAtMzNmNWY1ODU1ZjcyLTUwMDEwMDA5Nw==\/tiny\/Actuate-Therapeutics.png\" \/>\n<meta name=\"author\" content=\"Crypto Insider\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi\" \/>\n\t<meta name=\"twitter:data1\" content=\"Crypto Insider\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 ph\u00fat\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/\"},\"author\":{\"name\":\"Crypto Insider\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#\\\/schema\\\/person\\\/e81ca31713268a414ddbed321d3383d6\"},\"headline\":\"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development\",\"datePublished\":\"2024-10-29T22:39:00+00:00\",\"dateModified\":\"2024-10-29T22:43:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/\"},\"wordCount\":783,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development.gif\",\"articleSection\":[\"Business\",\"GlobeNewswire\"],\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/\",\"name\":\"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development - Crypto Insider\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development.gif\",\"datePublished\":\"2024-10-29T22:39:00+00:00\",\"dateModified\":\"2024-10-29T22:43:52+00:00\",\"description\":\"Crypto and Blockchain News\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/#breadcrumb\"},\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development.gif\",\"contentUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development.gif\",\"width\":1,\"height\":1},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/category\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Business\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/category\\\/business\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#website\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/\",\"name\":\"Crypto Insider\",\"description\":\"Crypto and Blockchain News\",\"publisher\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vi\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#organization\",\"name\":\"Crypto Insider\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Logo-crypto-insider.jpeg\",\"contentUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Logo-crypto-insider.jpeg\",\"width\":2048,\"height\":2048,\"caption\":\"Crypto Insider\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/yourcryptoinsider\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/vietnaminsider\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#\\\/schema\\\/person\\\/e81ca31713268a414ddbed321d3383d6\",\"name\":\"Crypto Insider\",\"description\":\"Tin t\u1ee9c v\u1ec1 Ti\u1ec1n \u0111i\u1ec7n t\u1eed v\u00e0 c\u00f4ng ngh\u1ec7 Blockchain\",\"sameAs\":[\"https:\\\/\\\/cryptoinsider.asia\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development","description":"Companies will discuss how Lantern\u2019s AI platform is being leveraged for the identification and\u00a0development of enrichment biomarkers for Actuate\u2019s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (\u201cActuate\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3\u03b2), announced that it will participate in \u201cWebinar Wednesday\u201d hosted by Lantern Pharma...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"Companies will discuss how Lantern\u2019s AI platform is being leveraged for the identification and\u00a0development of enrichment biomarkers for Actuate\u2019s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (\u201cActuate\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3\u03b2), announced that it will participate in \u201cWebinar Wednesday\u201d hosted by Lantern Pharma...","og_locale":"vi_VN","og_type":"article","og_title":"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development","og_description":"Companies will discuss how Lantern\u2019s AI platform is being leveraged for the identification and\u00a0development of enrichment biomarkers for Actuate\u2019s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (\u201cActuate\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3\u03b2), announced that it will participate in \u201cWebinar Wednesday\u201d hosted by Lantern Pharma...","og_url":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/","og_site_name":"Crypto Insider","article_publisher":"https:\/\/www.facebook.com\/yourcryptoinsider","article_published_time":"2024-10-29T22:39:00+00:00","article_modified_time":"2024-10-29T22:43:52+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/NmFhNzVkMmItNzY5MC00NzMwLWJiOTAtMzNmNWY1ODU1ZjcyLTUwMDEwMDA5Nw==\/tiny\/Actuate-Therapeutics.png","type":"","width":"","height":""}],"author":"Crypto Insider","twitter_card":"summary_large_image","twitter_misc":{"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi":"Crypto Insider","\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc":"4 ph\u00fat"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/#article","isPartOf":{"@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/"},"author":{"name":"Crypto Insider","@id":"https:\/\/cryptoinsider.asia\/#\/schema\/person\/e81ca31713268a414ddbed321d3383d6"},"headline":"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development","datePublished":"2024-10-29T22:39:00+00:00","dateModified":"2024-10-29T22:43:52+00:00","mainEntityOfPage":{"@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/"},"wordCount":783,"commentCount":0,"publisher":{"@id":"https:\/\/cryptoinsider.asia\/#organization"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/10\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development.gif","articleSection":["Business","GlobeNewswire"],"inLanguage":"vi","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/","url":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/","name":"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development - Crypto Insider","isPartOf":{"@id":"https:\/\/cryptoinsider.asia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/#primaryimage"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/10\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development.gif","datePublished":"2024-10-29T22:39:00+00:00","dateModified":"2024-10-29T22:43:52+00:00","description":"Crypto and Blockchain News","breadcrumb":{"@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/#breadcrumb"},"inLanguage":"vi","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/"]}]},{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/#primaryimage","url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/10\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development.gif","contentUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/10\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development.gif","width":1,"height":1},{"@type":"BreadcrumbList","@id":"https:\/\/cryptoinsider.asia\/vi\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cryptoinsider.asia\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/cryptoinsider.asia\/category\/news\/"},{"@type":"ListItem","position":3,"name":"Business","item":"https:\/\/cryptoinsider.asia\/category\/business\/"},{"@type":"ListItem","position":4,"name":"Actuate to Participate in Lantern\u2019s Pharma Webinar on AI-Driven Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/cryptoinsider.asia\/vi\/#website","url":"https:\/\/cryptoinsider.asia\/vi\/","name":"Crypto Insider","description":"Crypto and Blockchain News","publisher":{"@id":"https:\/\/cryptoinsider.asia\/vi\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cryptoinsider.asia\/vi\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vi"},{"@type":"Organization","@id":"https:\/\/cryptoinsider.asia\/vi\/#organization","name":"Crypto Insider","url":"https:\/\/cryptoinsider.asia\/vi\/","logo":{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/cryptoinsider.asia\/vi\/#\/schema\/logo\/image\/","url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2021\/11\/Logo-crypto-insider.jpeg","contentUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2021\/11\/Logo-crypto-insider.jpeg","width":2048,"height":2048,"caption":"Crypto Insider"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/yourcryptoinsider","https:\/\/www.linkedin.com\/company\/vietnaminsider"]},{"@type":"Person","@id":"https:\/\/cryptoinsider.asia\/#\/schema\/person\/e81ca31713268a414ddbed321d3383d6","name":"Crypto Insider","description":"Tin t\u1ee9c v\u1ec1 Ti\u1ec1n \u0111i\u1ec7n t\u1eed v\u00e0 c\u00f4ng ngh\u1ec7 Blockchain","sameAs":["https:\/\/cryptoinsider.asia"]}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/10\/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development.gif","jetpack-related-posts":[],"jetpack_likes_enabled":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts\/6719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/comments?post=6719"}],"version-history":[{"count":0,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts\/6719\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/media\/6720"}],"wp:attachment":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/media?parent=6719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/categories?post=6719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/tags?post=6719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}